Medical/Pharmaceuticals
Amaran Biotech's Vaccine Adjuvant AB-801 Receives FDA Drug Master File (DMF) Filing Acknowledgement
HSINCHU, Dec. 2, 2025 /PRNewswire/ -- Amaran Biotech, a next-generation Contract Development and Manufacturing Organization (CDMO), announced that its self-developed, GMP-grade high-purity vaccine adjuvantAB-801 has received an Acknowledgement Letter from the U.S. Food and Drug Administration (FD...
2025-12-02 14:42
983
Chula's Deep GI: AI Revolutionizes Gastrointestinal Cancers Detection
BANGKOK, Dec. 2, 2025 /PRNewswire/ -- The Faculty of Medicine
2025-12-02 10:40
1785
Lynk Pharmaceuticals Announces FDA IND Approval of Its Allosteric TYK2 Inhibitor LNK01006
HANGZHOU, China and SHANGHAI and BOSTON, Dec. 2, 2025 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as "Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on developing innovative therapies for immune and inflammatory diseases, today ann...
2025-12-02 08:00
2390
Ziwig Endotest®: Scientific Validation Published in NEJM Evidence
LYON, France, Dec. 2, 2025 /PRNewswire/ -- NEJM Evidence, a journal of the New England Journal of Medicine Group, has published an article titled "Validation of a Saliva microRNA Signature for Endometriosis," dedicated to the saliva-based diagnostic test developed by Ziwig. The publication repor...
2025-12-02 06:00
994
CQ Medical® Expands Radiation Therapy Portfolio With Bionix Business Unit Acquisition
AVONDALE, Pa., Dec. 2, 2025 /PRNewswire/ -- CQ Medical, the global leader in patient radiotherapy positioning and healthcare innovation, is proud to announce the acquisition of Bionix's Radiation Therapy business unit, marking an expansion of its patient positioning and marking product portfolio....
2025-12-02 02:07
899
Generate:Biomedicines to Initiate Global Phase 3 Studies of GB-0895, a Long-Acting Anti-TSLP Antibody for Severe Asthma Engineered with AI
SOLAIRIA-1 and SOLAIRIA-2 will evaluate GB-0895 in approximately 1,600 patients with severe asthma whose disease remains inadequately controlled on current therapies These are the first global Phase 3 studies of a long-acting anti-TSLP antibody, marking a pivotal step as GB-0895 advances the pro...
2025-12-01 19:00
1341
Lee's Pharm Supports Disaster Relief Efforts for Wang Fuk Court in Tai Po
HONG KONG, Dec. 1, 2025 /PRNewswire/ -- Lee's Pharmaceutical Holdings Limited (" Lee's Pharm" or the "Group", stock code: 0950.HK) expresses its deep condolences to the victims of the serious fire at Wang Fuk Court inTai Po, which caused multiple casualties and left many residents homeless and in ...
2025-12-01 18:46
1211
Hedia appoints new CEO: Rasmus Kofoed to succeed Lars Christian Lund
COPENHAGEN, Denmark, Dec. 1, 2025 /PRNewswire/ -- Danish diabetes‑tech company Hedia is implementing a leadership change effective1 December 2025, when Rasmus Kofoed will take over as Chief Executive Officer (CEO). He succeeds Lars Christian Lund, who after approximately 2 years in the role has d...
2025-12-01 16:00
1145
The Wisdom Derived from the Great Migration: Hakka Medicine - The Unique "Medical Epic" of the Hakka People
HONG KONG, Dec. 1, 2025 /PRNewswire/ -- From November 23rd to 25th, the 7th World Hakka Conference was held in Meizhou,Guangdong. With the theme "Gathering Global Hakka Businesspeople to Foster High-Quality Development," the conference adhered to the principles of "openness, innovation, cooperati...
2025-12-01 15:26
1631
Oxford Instruments launches Imaris 11: boosting research productivity with clear, workflow-driven image analysis
LONDON, Dec. 1, 2025 /PRNewswire/ -- Oxford Instruments announces the release of Imaris 11, the latest generation of its industry-leading 3D/4D microscopy image visualisation and analysis software. The new version introduces an intuitive Workflow system, enhanced batch processing, and advanced to...
2025-12-01 09:00
1443
MetaOptics Announces Strategic Share Placement to Accelerate Growth and Meet Rising Global Demand
SINGAPORE, Dec. 1, 2025 /PRNewswire/ -- MetaOptics Ltd (Catalist: 9MT) (" MetaOptics" or the "Company", and together with its subsidiaries, the "Group"), a leading-edge semiconductor optics company, announced that it is proposing to raiseS$4.85 million through a placement of 6,685,028 new ordinary...
2025-12-01 08:30
2571
The Science of Longevity: Inside Prof. Mike Chan's Vision for Living Stronger, Smarter, and Longer
BANGKOK, Dec. 1, 2025 /PRNewswire/ -- Malaysia had a rare moment of reflection
this year when former Prime Minister Tun Dr. Mahathir Mohamad turned 100. His
milestone sparked public conversations about aging, vitality, and what it truly
means to remain strong at any age.
2025-12-01 00:57
1984
The Bioregenerative Sports Revolution: How Prof. Mike Chan Is Changing Athlete Recovery -- From Sabah to the Super Bowl
KOTA KINABALU, Malaysia, Dec. 1, 2025 /PRNewswire/ -- Big changes often start
in small ways. For Sabah FC, a top Malaysian football club, it began with a
simple agreement — a partnership with European Wellness, a medical group best
known for anti-aging and precursor stem cell therapy.
2025-12-01 00:27
2092
Perlis Royalty Join Prof. Mike Chan in Strengthening Malaysia's Fight Against Autism
KUALA LUMPUR, Malaysia, Nov. 30, 2025 /PRNewswire/ -- Malaysia's drive to modernize autism care received strong support today when the Raja Muda of Perlis, Tuanku Syed Faizuddin Putra Jamalullail, and his consort, Tuanku Dr. Hajah Lailatul Shahreen Akashah Khalil, attended the International Congr...
2025-12-01 00:07
1778
Ascletis Selects Its First Oral GLP-1R/GIPR/GCGR Triple Peptide Agonist, ASC37, for Clinical Development
- Utilizing Ascletis' Peptide Oral Transport ENhancement Technology (POTENT), ASC37 oral tablets achieved average absolute oral bioavailability of 4.2%, approximately 9-, 30-, and 60-fold higher than semaglutide, tirzepatide, and retatrutide in the oral SNAC formulation, respectively, in head-to...
2025-11-30 18:15
2089
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
BEIJING, Nov. 28, 2025 /PRNewswire/ -- On November 28, 2025, Juventas Cell Therapy Co., Ltd. (hereinafter referred to as "Juventas") announced that its independently developed CAR-T cell therapy product, Inaticabtagene Autoleucel ( Ina-cel) (tradename: YORWIDATM), has received new drug marketing a...
2025-11-28 20:52
1529
K-Beauty & K-MediTech Expo Malaysia 2025 Concludes Successfully, Strengthening Korea-Malaysia Collaboration Across Beauty and Healthcare Sectors
PENANG, Malaysia, Nov. 28, 2025 /PRNewswire/ -- K-Beauty Expo Malaysia 2025 and K-MediTech Expo Malaysia 2025, hosted by Gyeonggi Province and organised by KINTEX, have successfully concluded at the Penang Waterfront Convention Centre (PWCC) after a dynamic three-day showcase of Korea's leading b...
2025-11-28 20:11
1625
Tianlong Strengthens Transfusion Safety with Innovative Blood Screening Solutions on World AIDS Day 2025
XI'AN, China, Nov. 28, 2025 /PRNewswire/ -- On World AIDS Day 2025, Tianlong reiterates its commitment to advancing global transfusion safety by presenting its fully integrated nucleic acid blood screening solution. Combining high automation with high-sensitivity NAT reagents, the solution enable...
2025-11-28 18:33
1469
OMRON Healthcare Surpasses 50 Million Nebulizers Sold
- Easing Burden of Respiratory Diseases Worldwide since 1978 - KYOTO, Japan, Nov. 28, 2025 /PRNewswire/ -- OMRON HEALTHCARE Co., Ltd., a global leader in the field of clinically proven, innovative medical equipment for home health monitoring and treatment, announced that cumulative sales of its ...
2025-11-28 16:00
1210
The Annals of Oncology Publishes Results of Phase II Study of Sacituzumab Tirumotecan Monotherapy for Urothelial Carcinoma
CHENGDU, China, Nov. 28, 2025 /PRNewswire/ -- Recently, Clinical study results from Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", HKEX: 6990)'s TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy for advanced or metastatic urothelial carcinoma (UC) patients has been publ...
2025-11-28 12:32
2506
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 327 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 308 media titles]
2026-02-26 09:30
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 298 media titles]
2026-02-26 19:57
Most Read
/C O R R E C T I O N -- Republic Power Group Limited (NASDAQ: RPGL)/
2026-02-20 06:36
8978
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
2026-02-20 07:27
8152